- Home
- DXR vs RADX Comparison
DXR vs RADX Comparison
Compare DXR & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- RADX
- Stock Information
- Founded
- DXR 1970
- RADX 2021
- Country
- DXR United States
- RADX Australia
- Employees
- DXR N/A
- RADX N/A
- Industry
- DXR Medical/Dental Instruments
- RADX
- Sector
- DXR Health Care
- RADX
- Exchange
- DXR Nasdaq
- RADX NYSE
- Market Cap
- DXR 36.4M
- RADX 32.5M
- IPO Year
- DXR N/A
- RADX N/A
- Fundamental
- Price
- DXR $9.49
- RADX $4.70
- Analyst Decision
- DXR Strong Buy
- RADX Strong Buy
- Analyst Count
- DXR 1
- RADX 2
- Target Price
- DXR $25.00
- RADX $13.50
- AVG Volume (30 Days)
- DXR 5.6K
- RADX 20.9K
- Earning Date
- DXR 01-01-0001
- RADX 02-26-2025
- Dividend Yield
- DXR N/A
- RADX N/A
- EPS Growth
- DXR 86.16
- RADX N/A
- EPS
- DXR 0.11
- RADX N/A
- Revenue
- DXR $119,714.00
- RADX $204,609.00
- Revenue This Year
- DXR N/A
- RADX N/A
- Revenue Next Year
- DXR N/A
- RADX N/A
- P/E Ratio
- DXR $82.80
- RADX N/A
- Revenue Growth
- DXR N/A
- RADX N/A
- 52 Week Low
- DXR $6.55
- RADX $3.50
- 52 Week High
- DXR $10.00
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- DXR 69.88
- RADX N/A
- Support Level
- DXR $8.68
- RADX N/A
- Resistance Level
- DXR $9.03
- RADX N/A
- Average True Range (ATR)
- DXR 0.47
- RADX 0.00
- MACD
- DXR 0.03
- RADX 0.00
- Stochastic Oscillator
- DXR 90.38
- RADX 0.00
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.